Bayer to Buy Cancer-Drug Partner Algeta for $2.9 Billion

Bayer AG agreed to buy Algeta ASA, its partner on the prostate-cancer medicine Xofigo, for about 17.6 billion kroner ($2.9 billion) to gain control of the drug and experimental radiation therapies.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.